Greenwich LifeSciences (GLSI) Amortizatization of Intangibles (2019 - 2025)
Greenwich LifeSciences' (GLSI) quarterly Amortizatization of Intangibles came in at $876.0 in Q2 2025, down 2.99% YoY from $903.0 in Q2 2024, and down 2.99% on a QoQ basis from $903.0 in Q1 2025.
Analysis
Greenwich LifeSciences (GLSI) Amortizatization of Intangibles (2019 - 2025) Analysis & Trends
Greenwich LifeSciences (GLSI) has 7 years of Amortizatization of Intangibles data on file, last reported at $876.0 in Q2 2025.
- Quarterly Amortizatization of Intangibles fell 2.99% year-over-year to $876.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $1779.0 (down 50.75% YoY) and the FY2025 annual result came in at $1779.0, down 50.75% from the prior year.
- Amortizatization of Intangibles slipped to $876.0 in Q2 2025, from $903.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $903.0 in Q1 2021 to a low of $876.0 in Q2 2025.
- A 5-year average of $901.5 and a median of $903.0 in 2021 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2021 — Amortizatization of Intangibles increased 0.22% — and 2025, when it retreated 2.99%.
- Tracing GLSI's Amortizatization of Intangibles over 5 years: stood at $903.0 in 2021, then changed by 0.0% to $903.0 in 2022, then changed by 0.0% to $903.0 in 2023, then changed by 0.0% to $903.0 in 2024, then decreased by 2.99% to $876.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $876.0 (Q2 2025), $903.0 (Q1 2025), and $903.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 876.00 |
| Mar 31, 2025 | 903.00 |
| Dec 31, 2024 | 903.00 |
| Sep 30, 2024 | 903.00 |
| Jun 30, 2024 | 903.00 |
| Mar 31, 2024 | 903.00 |
| Dec 31, 2023 | 903.00 |
| Sep 30, 2023 | 903.00 |
| Jun 30, 2023 | 903.00 |
| Mar 31, 2023 | 903.00 |
| Dec 31, 2022 | 903.00 |
| Sep 30, 2022 | 903.00 |
| Jun 30, 2022 | 903.00 |
| Mar 31, 2022 | 903.00 |
| Dec 31, 2021 | 903.00 |
| Sep 30, 2021 | 903.00 |
| Jun 30, 2021 | 903.00 |
| Mar 31, 2021 | 903.00 |
| Dec 31, 2020 | 903.00 |
| Sep 30, 2020 | 903.00 |